Kiniksa Pharmaceuticals Third Quarter 2026 Earnings Conference Call - KINIKSA PHARMACEUTICALS INTERNATIONAL PLC

Financial Performance:

• Q3 2026 revenue reached $286 million, representing a 58% year-over-year increase driven by Arclist sales.
• Net income surged to $47.3 million, with gross profit rising to $54.2 million.
• Collaboration profit (ARCLOS) increased 67% year-over-year to $211.6 million, outpacing sales growth.
• Company ended the quarter with $568.8 million in cash, generating approximately $43 million in net cash during the quarter.
• Total operating expenses rose due to increased cost of goods sold, collaboration expenses, R&D investment for KPL-387, and expanded SG&A for commercialization.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance raised to $1.045–$1.050 billion.
• Full-year 2026 R&D expenses projected at $160–$170 million, including pre-commercial manufacturing costs for KPL-387.
• Full-year 2026 SG&A expenses projected at $270–$280 million to support patient awareness and targeting.
• KPL-387 pivotal Phase 3 data expected in the second half of 2027, with a potential commercial launch in 2028–2029.
• KPL-1161 Phase 1 clinical trials targeted to begin by year-end 2026.
• Long-term goal remains establishing a profitable franchise with multiple commercial products and continued growth.

Business Segments and Product Lines:

• Arclist: Penetration rate in the recurrent pericarditis market reached 23% for the multiple recurrence patient population (approx. 14,000 annual patients) by end of Q3; ~20% of prescriptions are now in the first recurrence group.
• KPL-387: A once-monthly subcutaneous IL-1 alpha/beta inhibitor designed to transition patients from current therapies; pivot to monotherapy dosing study is ongoing to support label expansion.
• KPL-1161: A quarterly IL-1 alpha/beta inhibitor currently in development, targeting chronic disease states with extended dosing intervals.
• Commercial Execution: Prescriber base grew to 5,450 total (up 450 quarter-over-quarter), with repeat prescribers rising to 30% of the base.
• New Initiatives: Launched "Heart's Home" AI-driven direct-to-consumer campaign, resulting in a 12-fold increase in website traffic and an 8-fold increase in engaged sessions.

Market and Competitive Landscape:

• Target addressable market includes 40,000 annual recurrent pericarditis patients, with significant growth potential in the 26,000 first-recurrence segment.
• Physician sentiment has shifted, with 50% supporting earlier Arclist use post-NSAIDs/colchicine and pre-steroids, doubling from three years ago per 2025 ACC guidelines.
• Customer feedback indicates 75% of patients prefer the KPL-387 monthly auto-injector profile over current therapies, and 92% of physicians expressed high likelihood to prescribe it.
• Competition remains focused on standard of care (NSAIDs, colchicine, steroids), with the company driving a paradigm shift toward IL-1 inhibition.

Risks and Challenges:

• Forward-looking statements carry risks regarding actual results differing from projections.
• Clinical timelines are subject to enrollment and dosing dynamics in the ongoing global Phase 3 trial for KPL-387.
• Market penetration relies on continued adoption by prescribers and patient engagement, requiring sustained commercial investment.
• External BD opportunities face a high bar for value creation relative to internal homegrown pipeline assets.

Management Commentary and Tone:

• Management expressed strong confidence and excitement regarding Arclist's momentum and the "robust financial profile" enabling future investment.
• CEO Sanj Patel emphasized the team's commitment to helping more patients and building a leading IL-1 alpha/beta inhibition franchise.
• CFO Mark Ragosa highlighted the efficient nature of DTC spend and the profitability of the core business funding R&D.
• Tone was upbeat, citing "massive momentum" in clinical operations and commercial execution.

Analyst Questions and Answers:

• KPL-387 Enrollments: Management confirmed global site enrollment and dosing are proceeding robustly, citing strong engagement with investigators and a dedicated clinical operations team to support the H2 2027 data readout.
• Penetration Curve: Management noted penetration is growing steadily (from 18% to 23%) and emphasized the large remaining opportunity in both multiple and first-recurrence patient groups without significant demographic shifts.
• KPL-387 Study Design: Clarified the transition study is a posology study designed to inform the label for switching patients to a 300mg monthly subcutaneous monotherapy, following precedents set by Arclist.
• KPL-1161 Indications: No specific indications disclosed yet, but the quarterly dosing profile is expected to unlock chronic and lifelong disease states.
• Cash Deployment: Management reaffirmed a pragmatic approach to capital allocation, keeping BD opportunities as a secondary priority to internal pipeline growth but maintaining an open eye for value-accretive external opportunities.
• Prescriber Mix: Detailed Q3 growth driven by new prescribers (450 new additions) and increased repeat prescribing, though exact split between new vs. repeat new patient acquisition was not disclosed.

Other Key Points:

• The company highlighted the strategic shift toward AI and machine learning for both HCP targeting and DTC patient identification.
• The 2025 ACC Concise Clinical Guidance was cited as a key catalyst for changing physician prescribing behavior earlier in the treatment algorithm.
• Arclist is positioned to transition from a monotherapy option to a potential first-line treatment after standard therapies.